New Investigational Drug for Refractory Systemic Lupus Erythematosus Receives Clearance of IND Application for Phase 1/2 Clinical Trials from FDA
The U.S. Food and Drug Administration has cleared (when a clinical study sponsor receives approval to administer an investigational drug or biological product to humans) an application for a new investigational therapy, FasTCAR-T GC012F, for treatment of refractorysystemic lupus erythematosus. Researchers will initiate a Phase 1 / 2 clinical trial next year.
Using CD19/BCMA dual-targeting CAR-T cell therapy, the drug depletes disease-causing antibody producing cells and B cells (immune system cells involved in the production of autoantibodies and lupus disease activity). CAR T-cells are genetically altered cells and T-cells are part of the immune system. To make CAR-T cells, scientists create or engineer new cells called chimeric antigen receptors (CARs), and then introduce T-cells into them. FasTCAR-T GC012F has demonstrated favorable response in people with other immune system related diseases, including multiple myeloma, and B-cell non-Hodgkin lymphoma.
Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.